TF binding compound
OwnerSoren E. Bjorn, Else Marie Nicolaisen +1inventors
InventorsSoren E. Bjorn, Else Marie Nicolaisen, Thomas Dock Steenstrup
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds that bind to and inhibit the activity of tissue factor (TF) and mediate a cytolytic immune response.
Claims28
A compound having the formula A-(LM)-C, wherein A is a Factor VIIa (FVIIa) polypeptide;
- LM is an optional linker moiety;
- and C comprises an immunostimulatory effector domain;
- and wherein said compound binds to tissue factor (TF).
A pharmaceutical composition comprising (i) an amount of a compound having the formula A-(LM)-C, wherein A is a FVIIa polypeptide;
- LM is an optional linker moiety;
- C comprises an immunostimulatory effector domain;
- and wherein said compound binds to TF;
- and (ii) a pharmaceutically acceptable carrier or excipient.
A compound for use as a medicament having the formula A-(LM)-C, wherein A is a FVIIa polypeptide;
- LM is an optional linker moiety;
- C comprises an immunostimulatory effector domain;
- and wherein said compound binds to TF.
A method for preventing or treating disease or disorder associated with pathophysiological TF activity, said method comprising contacting a TF expressing cell with a compound having the formula A-(LM)-C, wherein A is a FVIIa polypeptide;
- LM is an optional linker moiety;
- C comprises an immunostimulatory effector domain;
- and wherein said compound binds to TF.
Dependencies are inferred from the claim text.